Navidea Biopharmaceuticals Inc (NAVB.A)
NAVB.A on American Stock Exchange
3.05USD
11:04am EDT
3.05USD
11:04am EDT
Price Change (% chg)
$0.01 (+0.33%)
$0.01 (+0.33%)
Prev Close
$3.04
$3.04
Open
$3.07
$3.07
Day's High
$3.07
$3.07
Day's Low
$3.05
$3.05
Volume
6,794
6,794
Avg. Vol
101,564
101,564
52-wk High
$4.08
$4.08
52-wk Low
$2.15
$2.15
About
Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company’s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of... (more)
Overall
| Beta: | 0.70 |
| Market Cap (Mil.): | $363.55 |
| Shares Outstanding (Mil.): | 119.59 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| NAVB.A | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.28 | -- | -- |
| ROI: | -213.92 | -2.58 | 18.76 |
| ROE: | -492.56 | -2.66 | 19.59 |
Navidea cancer imaging agent may see wider use
- Navidea Biopharmaceuticals Inc said its cancer diagnostic agent was effective in identifying the first lymph node reached by the disease in patients with head and neck cancer, paving the way to expand its use in all solid cancers.
Navidea cancer imaging agent may see wider use
April 4 - Navidea Biopharmaceuticals Inc said its cancer diagnostic agent was effective in identifying the first lymph node reached by the disease in patients with head and neck cancer, paving the way to expand its use in all solid cancers.
Competitors
| Price | Change | |
|---|---|---|
| Eli Lilly & Co. (LLY.N) | $53.41 | +0.30 |
| General Electric Company (GE.N) | $24.64 | +0.27 |
| Bayer AG (BAYGn.DE) | €89.43 | +2.08 |
| Bayer AG (BAYE.F) | -- | -- |
| Dynasil Corporation of America (DYSL.OQ) | $0.72 | -0.02 |
| C.R. Bard, Inc. (BCR.N) | $115.78 | +1.18 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: MacroRisk Analytics/EconomicInvestor
|
$15.00
|
|
Provider: TheStreet.com Ratings
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

